1. Home
  2. TPST vs RYOJ Comparison

TPST vs RYOJ Comparison

Compare TPST & RYOJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TPST
  • RYOJ
  • Stock Information
  • Founded
  • TPST 2011
  • RYOJ 2015
  • Country
  • TPST United States
  • RYOJ Japan
  • Employees
  • TPST N/A
  • RYOJ N/A
  • Industry
  • TPST Biotechnology: Pharmaceutical Preparations
  • RYOJ Professional Services
  • Sector
  • TPST Health Care
  • RYOJ Consumer Discretionary
  • Exchange
  • TPST Nasdaq
  • RYOJ Nasdaq
  • Market Cap
  • TPST 33.0M
  • RYOJ 32.5M
  • IPO Year
  • TPST N/A
  • RYOJ 2025
  • Fundamental
  • Price
  • TPST $10.16
  • RYOJ N/A
  • Analyst Decision
  • TPST Hold
  • RYOJ
  • Analyst Count
  • TPST 3
  • RYOJ 0
  • Target Price
  • TPST $30.00
  • RYOJ N/A
  • AVG Volume (30 Days)
  • TPST 111.5K
  • RYOJ 348.0K
  • Earning Date
  • TPST 08-11-2025
  • RYOJ 01-01-0001
  • Dividend Yield
  • TPST N/A
  • RYOJ N/A
  • EPS Growth
  • TPST N/A
  • RYOJ 72.91
  • EPS
  • TPST N/A
  • RYOJ 0.13
  • Revenue
  • TPST N/A
  • RYOJ $11,576,848.00
  • Revenue This Year
  • TPST N/A
  • RYOJ N/A
  • Revenue Next Year
  • TPST N/A
  • RYOJ N/A
  • P/E Ratio
  • TPST N/A
  • RYOJ $21.69
  • Revenue Growth
  • TPST N/A
  • RYOJ 5.60
  • 52 Week Low
  • TPST $5.35
  • RYOJ $2.41
  • 52 Week High
  • TPST $20.67
  • RYOJ $3.75
  • Technical
  • Relative Strength Index (RSI)
  • TPST 72.60
  • RYOJ N/A
  • Support Level
  • TPST $6.96
  • RYOJ N/A
  • Resistance Level
  • TPST $10.90
  • RYOJ N/A
  • Average True Range (ATR)
  • TPST 0.63
  • RYOJ 0.00
  • MACD
  • TPST 0.33
  • RYOJ 0.00
  • Stochastic Oscillator
  • TPST 81.24
  • RYOJ 0.00

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Share on Social Networks: